Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy

Claudia Giavoli1,2, Emanuele Ferrante 1,2, Eriselda Profka1,2, Luca Olgiati1,2, Silvia Bergamaschi1,2, Cristina L Ronchi1,2, Elisa Verrua1,2, Marcello Filopanti1,2, Elena Passeri4, Laura Montefusco1,3, Andrea G Lania1,2, Sabrina Corbetta4, Maura Arosio 1,3, Bruno Ambrosi 4, Anna Spada 1,2 and Paolo Beck-Peccoz1,2

1Department of Medical Sciences, University of Milan, Milan, Italy, 2Unit of Endocrinology Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, 20125 Milan, Italy, 3Unit of Endocrinology, Ospedale San Giuseppe Multimedica, 20123 Milan, Italy and 4Endocrinology Unit, Department of Medical and Surgical Sciences, University of Milan, IRCCS Policlinico San Donato, 20097 Milan, Italy

(Correspondence should be addressed to C Giavoli at Fondazione Ca` Granda-Ospedale Maggiore Policlinico, Endocrinology Unit-Department of Medical Sciences, Via Francesco Sforza, 35, 20122 Milan, Italy; Email: claudiagiavoli@yahoo.it)

Abstract

Objective: A common polymorphic variant of GH receptor (exon 3 deletion, d3GHR) has been linked with increased response to recombinant human GH (rhGH) in some patients with or without GH deficiency (GHD). The aim of the study was to investigate the impact of the GHR genotype on the phenotype of GHD adults and on the metabolic effect of rhGH therapy.

Design: Prospective study of GHD patients evaluated before and during short- (1 year, n = 100) and long-term (5 years, n = 50) rhGH therapy.

Methods: Effects of rhGH on IGF1 levels, body composition (body fat percentage, BF%), body mass index, lipid profile, and glucose homeostasis (fasting insulin and glucose, insulin sensitivity indexes) were evaluated according to the presence or the absence of the d3GHR variant.

Results: The different genotype did not influence basal phenotype of GHD. Short-term rhGH determined normalization of IGF1 levels, decrease in BF%, and worsening of insulin sensitivity, independently from the presence of the d3GHR allele. A significant increase in high-density lipoprotein cholesterol occurred in the d3GHR group. Normalization of IGF1 levels and decrease in BF% were maintained after 5 years. Insulin sensitivity restored to basal values, though in d3GHR patients fasting glucose remained significantly higher than at baseline. After both 1 and 5 years, percentage of subjects with impaired glucose tolerance, similar in the two groups at baseline, decreased in fl/fl while doubled in d3GHR patients. In this last group, a long-term significant reduction in total and low-density lipoprotein cholesterol was also observed.

Conclusion: The functional difference of d3GHR may influence some metabolic effects of rhGH on GHD adults.

European Journal of Endocrinology 163 361–368

Introduction

A polymorphism in the GH receptor (GHR) gene consisting of genomic exon 3 deletion or retention has been described in humans (1). This polymorphism gives rise to the exon 3 deleted (d3GHR) or full-length (fl-GHR) isoforms. The d3GHR isoform shows increased receptor activity due to an enhanced signal transduction (2). The prevalence of the d3 allele in the general population is estimated to be 25–32%, with a frequency of homozygosity of 9–14% (1, 2). Recently, it has been observed that this polymorphism is linked to enhanced response to recombinant human GH (rhGH) in term of height in children with idiopathic short stature, in those born small for gestational age (SGA) and in girls with Turner syndrome (3, 4). These results have not been confirmed in two out of three reports (5, 6) examining children with idiopathic GH deficiency (GHD) and in other studies evaluating children born SGA (7). The reason for the above-mentioned discrepancies may be related to the small number of subjects evaluated in some reports, to the different studies’ protocol and design, or to the different rhGH dosage schedules.

Indeed, a meta-analysis of all these studies provided a more consistent picture on this topic. From 136 initially screened papers, authors finally included 16 reports,
homogenous for study design and end points. Their conclusion was that the d3GHR polymorphism is associated with increased basal height in GHD but not in non-GHD short children, and with the higher growth response to 1-year rhGH therapy in both GHD and non-GHD children (8). Up to now, three studies have been performed in GHD adults to verify a possible role of GHR polymorphism in the interindividual variability of the response to rhGH. Only one of these reports evaluated the long-term response to rhGH, and none examined the changes in glucose metabolism (9–11). GHD in adults is a clinical syndrome characterized by several metabolic alterations (increased body fat percentage (BF%), impaired physical performance, altered lipid profile, and insulin resistance) most of which reversed by rhGH replacement therapy (12, 13). Nowadays, it is well established that to optimize benefits minimizing side effects, rhGH replacement therapy should be started with low doses, thereafter titrated and individualized according to insulin-like growth factor 1 (IGF1) levels and clinical conditions of the patients (14, 15). Indeed, the individual response to rhGH remains highly variable, and some effects of replacement therapy, for example, on glucose metabolism, are still a matter of debate. In fact, while it is well known that GH influences glucose homeostasis through increased lipolysis and insulin antagonism (16), low GH and IGF1 levels are associated with impaired glucose tolerance (IGT) in adults (17). Several reports have evaluated the effects of rhGH replacement on glucose metabolism in GHD adults, mostly documenting a short-term and transient deterioration of insulin sensitivity with a successive long-term stabilization, probably due to the persistent reduction in BF%, as also confirmed by a study performed by our group (18).

The aim of the present study was to investigate a possible influence of this polymorphism on the phenotype of GHD adults, with particular focus on short- and long-term GH effects on glucose metabolism, body composition, and lipid profile.

Materials and methods

Patients and study design

This was a prospective open-label study in GHD adults. A total of 100 consecutive patients (M=62, F=38, mean age 46±13 years) were recruited. Diagnosis of severe GHD was defined by GH peak <3 µg/l to insulin tolerance test (19) or <11.5 µg/l if body mass index (BMI) was below 25 kg/m², <8.0 µg/l if BMI was between 25 and 30 kg/m², and <4.2 µg/l if BMI was over 30 kg/m² to arginine + GHRH test (20). The causes of GHD were nonfunctioning pituitary adenoma (n=35), prolactinoma (n=20), craniopharyngioma (n=16), GH-secretting adenoma (n=8), Cushings disease (n=5), idiopathic (n=7), primary empty sella (n=3), traumatic brain injury (n=2), Rathke cleft cysts (n=2), and other hypothalamic–pituitary diseases (n=2, one meningioma and one histiocytosis). All patients with childhood-onset GHD (n=10) were appropriately retested before the beginning of rhGH replacement in adult life.

Seven patients had isolated GHD, and 93 had multiple pituitary hormone deficiencies variously associated. Diabetes insipidus was present in 22% of the whole group. When necessary, conventional hormone replacement therapy for other pituitary hormone deficiencies was given at stable doses for at least 3 months before beginning rhGH therapy. Moreover, since it is known that rhGH therapy may unmask or worsen a central hypothyroid or hypoadrenal state (21, 22), both hypothalamus–pituitary–thyroid and adrenal axis were reevaluated not later than 6 months after the beginning of rhGH, and replacement therapy was started or adjusted when necessary. Short-term effects (1 year) were evaluated in all 100 patients, whereas in 50 of them a 5-year follow-up was available due to an earlier starting date of rhGH.

An individualized protocol of rhGH dose was used, above all according to sex and age of patients. Initial mean rhGH dose was 0.31±0.18 mg/day, then individually titrated against IGF1 levels between 0 S.D. and below the upper limit of the age- and sex-related reference range. In women, also use and route of estrogens were considered. Mean rhGH dose was 0.33±0.15 and 0.44±0.26 mg/day after 1 and 5 years respectively to maintain the above-mentioned IGF1 S.D.

Informed consent was obtained from all participants, and the study was approved by the local ethics committee.

Study parameters and assays

In all the patients, several metabolic parameters and cardiovascular risk factors, such as systolic and diastolic blood pressure (SBP and DBP), serum glucose and insulin before and after 2-h oral glucose tolerance test (OGTT) (in a subgroup of 62 and 27 subjects after 1 and 5 years respectively), HbA1c, and lipid profile (total and high-density lipoprotein (HDL) cholesterol, and triglycerides (TG)), were evaluated. Insulin resistance and sensitivity degree were determined using the homeostasis model assessment (HOMA-IR = FI (mU/l) × FG (mmol/l)/22.5) and the quantitative insulin check index (QUICKI = 1/(log FG (mg/dl)+log FI (mU/l))) (23, 24). Serum IGF1 concentrations were measured by a commercial RIA kit, supplied by Mediagnost, Tubingen, Germany, sensitivity 0.01 nmol/l and the intra- and interassay coefficient of variation 3.2 and 7.4% respectively. All the other biochemical parameters were measured by standard procedures. Low-density lipoprotein (LDL) cholesterol levels were evaluated by the formula: \( \text{LDLc} = \text{total cholesterol} - \text{HDLc} - \text{TG}/5 \).
Anthropometric measurements

Body composition was evaluated by whole-body bioelectrical impedance analysis, using a portable impedance analyser (RJL Systems, Detroit, MI, USA), following the instruction given by the manufacturer. BF% was calculated using Segal’s regression equation (25), and the results were compared with those reported by Pichard and co-workers (26) in normal subjects matched for age and sex.

BMI was calculated as weight in kilograms divided by the square of height in meters.

DNA extraction and genetic analysis

Leukocyte DNA was extracted from blood samples and collected from patients during one periodic medical examination, using Nucleon BACC2 genomic DNA purification kit (GE Healthcare, Piscataway, NJ, USA) in compliance with the manufacturer’s instructions. A multiplex PCR was carried out with the following primers: G1 5'-TTGGCTGCTTCGCTGGTCTG-3', G2 5'-AGTGTTTCTGAGCAGAGA-3', and G3 5'-CTTGGAATTAACACTTTGACAGACTC-3', as previously described (1). PCR was carried out in a 50-μl reaction mix with Platinum Taq (Invitrogen) and subjected to denaturation at 94°C for 2 min, followed by 39 cycles of 94°C for 30 s, 57°C for 30 s and 68°C for 30 s, and a final extension phase at 68°C for 10 min. Amplification products were subsequently run on 1% agarose gel electrophoresis and stained with ethidium bromide. In patients with flGHR gene, two bands of ~935 bp were produced. The occurrence of genomic deletion of exon 3 removed the annealing of G3 primer and resulted in a 250-bp band.

Statistical analysis

Calculations were performed by SPSS for Windows, version 17.0 (SPSS, Paris, France). Data are expressed as mean ± S.D., whereas proportion and frequencies were used for categorical variables. Frequency plots of all the data were visually inspected in order to assess the distribution of each variable in this study. Normal distributed variables were compared using Student’s t-test between the two groups of patients bearing or not the d3GHR allele and within each group at 0–12–60 months. Levene’s test was performed first to check the equality of variances. The contingency table derived from dichotomic data was tested by Fisher’s exact test. A two-tail P < 0.05 was considered statistically significant. In multiple comparisons tests, the Bonferroni correction of α value was used.

Results

Baseline: GHD genotype and phenotype

Forty-eight patients (48%) were GHR full-length homozygote (fl/fl), 45 patients (45%) were heterozygote (fl/d3), and 7 patients (7%) were homozygote for the d3 deleted form of GHR (d3/d3). Allele frequencies were distributed under Hardy–Weinberg equilibrium. Based on the genotype and according to the hypothesis of the dominant model (2), patients bearing the d3 allele in homozygous (d3/d3) and heterozygous (fl/d3) were grouped together, indicated as d3GHR, and compared with the group of patients bearing two wild-type alleles (fl/fl).

At baseline, most of the patients had IGF1 levels below the normal range for age and sex (79%), and increased BF% (68%). As far as cardiovascular risks factors are concerned, half of the patients (n = 50, 22 fl/fl and 28 d3GHR) had total cholesterol levels >200 mg/dl. 34% of patients (n = 34, 16 fl/fl and 18 d3GHR) showed low HDL cholesterol (<40 and <50 mg/dl, in males and females respectively), and 30% (n = 30, 15 fl/fl and 15 d3GHR) had TG levels >150 mg/dl. Moreover, 20% of patients (n = 20, 12 fl/fl and 8 d3GHR) had blood pressure >130/85 mmHg. At the beginning of the study, 12 subjects (seven fl/fl and five fl/d3) were taking antihypertensive drugs, and 6 subjects (three fl/fl and three fl/d3) were lipid-lowering agents. These therapies remained unchanged throughout the study. As far as glucose metabolism, none of the patients was affected with diabetes mellitus, only in two subjects (both belonging to d3GHR group) fasting glucose (FG) was ≥100 mg/dl (100 and 105 mg/dl). Among the 62 subjects evaluated by OGTT, ten patients (five fl/fl and five d3GHR) showed IGT. No difference was observed in all evaluated parameters between the two different phenotypes. Demographic and clinical data, as well as comparison of basal parameters between the two different genotypes, are shown in Table 1.

Short-term effects of rhGH and pharmacogenetics

After 1 year of rhGH replacement, in the whole group of patients, IGF1 levels significantly increased (from 80.1 ± 40.2 to 177.7 ± 70.6 ng/ml, P < 0.01) and normalized while BF% significantly decreased (from 32 ± 8.2 to 30 ± 8%, P < 0.01). FG and fasting insulin (FI) significantly increased (from 81.3 ± 8.7 to 85.3 ± 8.6 mg/dl, and from 9.3 ± 7 to 11.2 ± 9.3 μIU/ml respectively, P < 0.01), thus reflecting in a short-term
worsening of insulin sensitivity, mirrored by a significant increase in HOMA-IR (from 1.9 ± 1.5 to 2.4 ± 2, \( P < 0.01 \)), and by a significant decrease in QUICKI (from 0.37 ± 0.05 to 0.36 ± 0.04, \( P < 0.01 \)). A significant increase in mean post-OGTT glucose levels was also observed (from 110 ± 31 to 121 ± 34 mg/dl, \( P < 0.05 \)) and the percent of patients showing IGT increased from 16 to 21\% (\( n=13; \) three fl/fl and ten d3GHR). It is noteworthy that the number of patients with IGT reduced in the fl/fl group while doubled in the d3GHR (from five to ten subjects), though this difference was not significant at Fisher’s test (Fig. 1). During short-term therapy BMI, HbAlc, total, HDL, and LDL cholesterol, and SBP remained unchanged. However, when analyzing the effect of rhGH separately in the two genotype group (d3GHR or fl/fl), in the d3GHR group, a significant increase in HDL cholesterol was observed (from 50 ± 15.7 to 54.5 ± 17.7 mg/dl, \( P < 0.05 \)), while no difference occurred in fl/fl subjects (from 52.9 ± 17.3 to 50.1 ± 15.6 mg/dl, \( P=NS \)). Moreover, a significant reduction in DBP was recorded only in the fl group (from 79.7 ± 9.2 to 77 ± 7.85, \( P=0.012 \)).

Short-term rhGH effects in the two different genotypes are shown in Table 2. No difference versus basal conditions was observed in both groups in all the other evaluated parameters.

**Long-term effects of rhGH and pharmacogenetics**

In the 50 patients evaluated after the long-term treatment, the IGF1 increase and the BF% decrease persisted after 5 years of rhGH therapy (from 82.3 ± 44.9 to 163.2 ± 57.8 mg/ml and from 32.5 ± 8.6 to 27.7 ± 8.3% respectively, \( P < 0.01 \)). Contrary to what was observed in the short-term period, a significant reduction in both total and LDL cholesterol occurred in all patients (from 208.1 ± 48.99 to 191.3 ± 41.4 mg/dl and from 134.9 ± 44.6 to 111.3 ± 45.9 mg/dl, respectively, \( P < 0.01 \)). However, when analyzing separately the two genotype groups, the reduction in total cholesterol levels was significant only in d3GHR patients (from 208.3 ± 50 to 188.6 ± 40.99 mg/dl, \( P < 0.01 \)) and from 205.13 ± 48 to 192.3 ± 42.5, \( P=NS \), in d3GHR and fl/fl, respectively). As far as rhGH on glucose metabolism are concerned, examining the whole group of patients, both FG and FI levels returned toward baseline, reflecting a long-term restoration of insulin sensitivity indexes (HOMA-IR and QUICKI). However, evaluating rhGH effects according to genotype, in the d3GHR patients, FG levels remained significantly higher than at baseline, as observed in the short-term (77.8 ± 7.6 to 82.3 ± 9 mg/ml, at baseline and after 5 years respectively, \( P=0.024 \)). Long-term rhGH effects in the two genotype groups are shown in Table 3 and Fig. 2. In 27 patients (11 fl/fl and 16 d3GHR), data on post-OGTT glucose levels were available both at baseline and in the long-term period. Before rhGH, seven patients (five fl/fl and two d3GHR, 26\%) showed IGT. As observed in the short-term, after 5 years, even though the percentage of patients with IGT did not change, its distribution between the two genotype groups showed an inverse effect of rhGH on glucose tolerance. Indeed, the number of patients with IGT decreased in fl/fl
Table 2 Effects of recombinant human GH (rhGH) during short-term (1 year) treatment in GH deficiency (GHD) adults according to the different GH receptor (GHR) genotype.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1 year</th>
<th>P value*</th>
<th></th>
<th>Baseline</th>
<th>1 year</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>31/21</td>
<td>31/21</td>
<td>NS</td>
<td>31/17</td>
<td>31/17</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.7 ± 3.8</td>
<td>26.8 ± 3.8</td>
<td>NS</td>
<td>27.4 ± 4.2</td>
<td>27.7 ± 4.3</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>BF%</td>
<td>33.3 ± 9.5</td>
<td>30.7 ± 9.1</td>
<td>&lt;0.01</td>
<td>31.1 ± 6.6</td>
<td>29.3 ± 6.7</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>WC (cm)</td>
<td>91 ± 13</td>
<td>91 ± 13</td>
<td>NS</td>
<td>95 ± 13</td>
<td>94 ± 13</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>IGF1 (ng/ml)</td>
<td>73.0 ± 35.7</td>
<td>171.9 ± 62.9</td>
<td>&lt;0.01</td>
<td>87.2 ± 44.1</td>
<td>184.4 ± 78.6</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>FG (mg/dl)</td>
<td>80.9 ± 8.7</td>
<td>84.6 ± 7.5</td>
<td>0.001</td>
<td>81.6 ± 8.9</td>
<td>85.8 ± 9.7</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>FI (µIU/ml)</td>
<td>9.9 ± 8.7</td>
<td>11.3 ± 9.3</td>
<td>NS</td>
<td>9.8 ± 5.1</td>
<td>11.2 ± 9.4</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HbA1c %</td>
<td>5.1 ± 0.7</td>
<td>5.2 ± 0.7</td>
<td>NS</td>
<td>5.1 ± 0.6</td>
<td>5.1 ± 0.6</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.0 ± 1.8</td>
<td>2.4 ± 1.9</td>
<td>0.010</td>
<td>2.0 ± 1.1</td>
<td>2.4 ± 2.2</td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.36 ± 0.04</td>
<td>0.35 ± 0.02</td>
<td>0.012</td>
<td>0.36 ± 0.04</td>
<td>0.35 ± 0.03</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>T-chol (mg/dl)</td>
<td>210 ± 43</td>
<td>212 ± 41</td>
<td>NS</td>
<td>210 ± 47</td>
<td>202 ± 44</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HDL-chol (mg/dl)</td>
<td>50 ± 16</td>
<td>54 ± 18</td>
<td>0.012</td>
<td>53 ± 17</td>
<td>50 ± 16</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>131 ± 60</td>
<td>135 ± 50</td>
<td>NS</td>
<td>134 ± 73</td>
<td>131 ± 51</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>120 ± 15</td>
<td>119 ± 14</td>
<td>NS</td>
<td>123 ± 14</td>
<td>123 ± 14</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>77 ± 9</td>
<td>78 ± 8</td>
<td>NS</td>
<td>80 ± 9</td>
<td>77 ± 8</td>
<td>0.025</td>
<td></td>
</tr>
</tbody>
</table>

d3GHR, d3Fl (n = 45) and d3Fl (n = 7); M, male; F, female; BMI, body mass index; BF, body fat; WC, waist circumference; FG, fasting glucose; FI, fasting insulin; Chol, cholesterol; TG, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure. *P < 0.025 was considered statistically significant according to Bonferroni’s correction.

Discussion

In the present study, we investigated a possible influence of GHR polymorphism on the phenotype of GHD adults and on the metabolic effects of short- and long-term rhGH replacement. Among the studies performed up to now, only one examined long-term rhGH effects, and none extensively evaluated glucose metabolism (8–10). Various studies have evaluated the relationship between efficacy of rhGH therapy and the d3GHR polymorphism in different cohorts of short-GHD and non-GHD children, reporting conflicting results (4–7). A recent meta-analysis of all these studies summarized that the d3GHR polymorphism is associated with increased basal height in GHD but not in non-GHD short children, and with the higher growth response to 1-year rhGH therapy in both GHD and non-GHD children.

Table 3 Effects of recombinant human GH (rhGH) during long-term (5 years) treatment in GH deficiency (GHD) adults according to the different GH receptor (GHR) genotypes.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>5 years</th>
<th>P value*</th>
<th></th>
<th>Baseline</th>
<th>5 years</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>18/8</td>
<td>18/8</td>
<td>NS</td>
<td>16/8</td>
<td>16/8</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.5 ± 4.5</td>
<td>27.2 ± 4.8</td>
<td>NS</td>
<td>29.1 ± 3.9</td>
<td>29.6 ± 4.2</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>BF%</td>
<td>31.8 ± 10.7</td>
<td>26.8 ± 10.4</td>
<td>&lt;0.01</td>
<td>33.1 ± 5.7</td>
<td>28.7 ± 4.9</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>WC (cm)</td>
<td>90 ± 7</td>
<td>91 ± 17</td>
<td>&lt;0.01</td>
<td>94 ± 14</td>
<td>93 ± 16</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>IGF1 (ng/ml)</td>
<td>72.4 ± 42.4</td>
<td>160.1 ± 51.3</td>
<td>&lt;0.01</td>
<td>93.1 ± 46.0</td>
<td>166.1 ± 65.1</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>FG (mg/dl)</td>
<td>77.8 ± 7.6</td>
<td>82.3 ± 9</td>
<td>0.024</td>
<td>82.7 ± 8.6</td>
<td>85 ± 17</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>FI (µIU/ml)</td>
<td>11.0 ± 10.7</td>
<td>9.9 ± 9.6</td>
<td>NS</td>
<td>10.7 ± 5.5</td>
<td>11.1 ± 8.6</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HbA1c %</td>
<td>5.0 ± 0.7</td>
<td>5.2 ± 0.5</td>
<td>0.023</td>
<td>5.1 ± 0.6</td>
<td>5.2 ± 0.8</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.2 ± 2.2</td>
<td>2.0 ± 1.9</td>
<td>NS</td>
<td>2.2 ± 1.2</td>
<td>2.6 ± 2.9</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.40 ± 0.06</td>
<td>0.40 ± 0.10</td>
<td>NS</td>
<td>0.35 ± 0.04</td>
<td>0.40 ± 0.10</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>T-chol (mg/dl)</td>
<td>208 ± 50</td>
<td>189 ± 41</td>
<td>0.001</td>
<td>205 ± 48</td>
<td>192 ± 42</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>HDL-chol (mg/dl)</td>
<td>45 ± 11</td>
<td>58 ± 49</td>
<td>NS</td>
<td>47 ± 16</td>
<td>47 ± 11</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>133 ± 71</td>
<td>126 ± 54</td>
<td>NS</td>
<td>144 ± 73</td>
<td>135 ± 59</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>LDL-chol (mg/dl)</td>
<td>136 ± 35</td>
<td>105 ± 53</td>
<td>0.004</td>
<td>131 ± 44</td>
<td>118 ± 37</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>118 ± 15</td>
<td>115 ± 15</td>
<td>NS</td>
<td>124 ± 11</td>
<td>125 ± 20</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76 ± 8</td>
<td>74 ± 8</td>
<td>NS</td>
<td>82 ± 9</td>
<td>80 ± 12</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

d3GHR, d3Fl (n = 26) and d3Fl (n = 24); M, male; F, female; BMI, body mass index; BF, body fat; WC, waist circumference; FG, fasting glucose; FI, fasting insulin; Chol, cholesterol; TG, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure. *P < 0.025 was considered statistically significant according to Bonferroni’s correction.
While these results indicate the presence of these receptor variants as one of the main factors contributing to the growth response to rhGH therapy in children, its role is more uncertain in GHD adults. Indeed, the assessment of a possible influence of this polymorphism in GHD-deficient adults is quite difficult, since in these patients there is no marker of rhGH effectiveness that is as specific as growth velocity and final height for children.

Though no substantial difference was observed in basal evaluation, results of the present report suggest that rhGH replacement may influence at least some metabolic parameters typical of GHD adult syndrome in a slightly different manner, according to the presence/absence of the d3GHR polymorphism. In particular, the long-term decrease in total and LDL cholesterol observed in the whole cohort of patients remained statistically significant only in patients bearing at least one d3GHR allele, when analysing rhGH effects separately in the two genotype groups. This suggests an enhanced lipid-lowering effect of rhGH in this subgroup of subjects.

The present result is in contrast to that previously reported by the only study evaluating short- and long-term metabolic effects of rhGH and suggesting that d3GHR is associated with differences in the efficacy of short-term rhGH replacement but not long-term rhGH replacement. These authors reported a higher increase in IGF1 levels and a lower decrease in total and LDL cholesterol in the d3GHR group in comparison with fl/fl (9). It is plausible that further studies are needed to explain the discrepancy between our results and those previously reported by van der Klaauw and colleagues (9). The major effect of rhGH in the d3GHR group might be explained by the reported enhanced activity of the d3 receptor isoform (2). This enhanced activity may mediate the metabolic effects of rhGH replacement not only on lipid metabolism, but also on glucose homeostasis. Indeed, present results suggest that patients bearing at least one d3 allele are more susceptible to the negative effect of rhGH on glucose metabolism. Though the effects of rhGH on glucose homeostasis are matter of debate, most studies on this topic indicate that in the short-term, there is a worsening of insulin sensitivity, while long-term rhGH therapy has a positive or at least a neutral effect (17, 27, 28). In the present group of patients evaluated after both 1 and 5 years, the short-term worsening of insulin sensitivity documented by the increase in FG levels and by the significant decrease in QUICKI was not followed by a long-term restoration if at least one d3 allele was present. As far as the OGTT is concerned, the presence of the d3GHR allele seems to be associated with a major tendency to develop IGT both after short- and long-term rhGH replacement. No data evaluating a possible influence of d3GHR polymorphism on glucose tolerance in GHD adults are available in the literature. Conversely, a recent study performed in acromegalic patients reported a higher proportion of patients with normal glucose tolerance (NGT) in the group of subjects bearing at least one d3GHR allele (29). This last data, along with the finding that the GHRd3 allele has a low frequency in the diabetic population, suggest a positive effect of this isoform on glucose metabolism (30). The divergent influence of the d3GHR polymorphism on glucose metabolism observed in GHD or excess underlines the notion that acromegaly and adult GHD are not simply two conditions characterized by different entities of GH secretion. All these observations seem to support the hypothesis that the d3GHR polymorphism may influence at least some metabolic effect of GH. Conversely, results from the present study indicate that the most relevant effects of rhGH, normalization of IGF1 levels and BF%, are not influenced by the

---

**Figure 2** Long-term modifications of metabolic parameters in the two different genotype groups.
GHR polymorphism. In fact, when analyzing the pharmacogenetic role of d3GHR, no difference in rhGH dosage to IGF1 (or delta-IGF1) correlations between d3GHR and fl/flGHR groups was found, in both short- and long-term treatment. This finding is in line with results reported in other studies, which examined rhGH effects only in the short-term (from 12 to 18 months). In particular, Barbosa et al. (10) evaluated a wide cohort of GHD adults before and after a 12-month period of rhGH treatment. Using IGF1 levels and BF as endpoints, the authors found that the presence of the d3GHR allele did not influence the response to GH replacement in GHD adults (10). Similarly, Adetunji et al. (11) showed that GHR isoform does not influence the rhGH dose required to optimize IGF1 and body composition. Moreover, this study first examined also the quality of life (QoL), concluding that the presence of the d3 allele does not influence patient response to treatment as determined by their QoL scores.

In conclusion, this study further supports the view that GHR polymorphism does not play a crucial role in determining the interindividual variability of the response to rhGH replacement in terms of IGF1 levels, body composition, and other related anthropometric parameters in GHD adults. However, the present data suggest that the functional difference of d3GHR, consisting in an enhanced signal transduction, may cause a major sensitivity to the metabolic effects of rhGH either in decreasing total and LDL cholesterol or in worsening glucose tolerance. Indeed, the finding that patients with at least one d3 allele are more susceptible to rhGH effects on glucose homeostasis may for instance represent an alert for a more strict and careful monitoring, being the effects of rhGH on insulin sensitivity still a matter of debate. Ongoing studies will widen the long-term group, and maybe give more strength to present results and better clarify the still controversial relationship between GHD, rhGH replacement, and glucose homeostasis. Further studies, also at a molecular level, may help to better clarify the role of this common polymorphism.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was partially supported by Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico.

References
2 Dos Santos SC, Essioux L, Teinturier C, Tauber M, Goffin V & Bouguerens F. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genetics 2004 36 720–724. (doi:10.1038/ng1379)

www.eje-online.org


Received 24 June 2010 Accepted 30 June 2010